Gatti M.; De Ponti F., Drug repurposing in the covid-19 era: Insights from case studies showing pharmaceutical peculiarities, «PHARMACEUTICS», 2021, 13, Article number: 302, pp. 1 - 23 [articolo]Open Access
Donker E.; Brinkman D.; Richir M.; Papaioannidou P.; Likic R.; Sanz E.J.; Christiaens T.; Costa J.; De Ponti F.; Gatti M.; Bottiger Y.; Kramers C.; Garner S.; Pandit R.; Van Agtmael M.; Tichelaar J., European List of Essential Medicines for Medical Education: A protocol for a modified Delphi study, «BMJ OPEN», 2021, 11, Article number: e045635, pp. 1 - 4 [articolo]Open Access
Conti N.; Gatti M.; Raschi E.; Diemberger I.; Potena L., Evidence and current use of levosimendan in the treatment of heart failure: Filling the gap, «DRUG DESIGN, DEVELOPMENT AND THERAPY», 2021, 15, pp. 3391 - 3409 [articolo]Open Access
Gatti M.; Raschi E.; De Ponti F., Fluoroquinolones and Aortic Disease, «JAMA INTERNAL MEDICINE», 2021, 181, pp. 880 - 881 [articolo]
Cojutti P.G.; Gatti M.; Rinaldi M.; Tonetti T.; Laici C.; Mega C.; Siniscalchi A.; Giannella M.; Viale P.; Pea F., Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization, «FRONTIERS IN PHARMACOLOGY», 2021, 12, Article number: 781892, pp. 1 - 11 [articolo]Open Access
Gatti, Milo; Raschi, Emanuel; Moretti, Ugo; Ardizzoni, Andrea; Poluzzi, Elisabetta; Diemberger, Igor, Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase, «VACCINES», 2021, 9, Article number: 19, pp. 1 - 13 [articolo]Open Access
Gatti M.; Turrini E.; Raschi E.; Sestili P.; Fimognari C., Janus kinase inhibitors and coronavirus disease (Covid)‐19: Rationale, clinical evidence and safety issues, «PHARMACEUTICALS», 2021, 14, Article number: 738, pp. 1 - 22 [articolo]Open Access
Gatti M.; Pea F., Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors, «EXPERT REVIEW OF CLINICAL PHARMACOLOGY», 2021, 14, pp. 583 - 599 [articolo]
Giannella M.; Malosso P.; Scudeller L.; Bussini L.; Rebuffi C.; Gatti M.; Bartoletti M.; Ianniruberto S.; Pancaldi L.; Pascale R.; Tedeschi S.; Viale P.; Paul M., Quality of care indicators in the MAnageMent of BlOOdstream infections caused by Enterobacteriaceae (MAMBOO-E study): state of the art and research agenda, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2021, 57, Article number: 106320, pp. 1 - 9 [articolo]
Meschiari, Marianna; Volpi, Sara; Faltoni, Matteo; Dolci, Giovanni; Orlando, Gabriella; Franceschini, Erica; Menozzi, Marianna; Sarti, Mario; Del Fabro, Giovanni; Fumarola, Benedetta; Guarneri, Francesco; Lanza, Paola; Lorenzotti, Silvia; Saccani, Barbara; Signorini, Liana; Van Hauwermeiren, Evelyn; Gatti, Milo; Pea, Federico; Castelli, Francesco; Mussini, Cristina, Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections, «JAC-ANTIMICROBIAL RESISTANCE», 2021, 3, Article number: dlab188, pp. 1 - 5 [articolo]Open Access
Gatti M.; Andreoni M.; Pea F.; Viale P., Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: A careful appraisal beyond approved indications focusing on unmet clinical needs, «DRUG DESIGN, DEVELOPMENT AND THERAPY», 2021, 15, pp. 3349 - 3378 [articolo]Open Access
Gatti M.; Raschi E.; De Ponti F., Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis, «EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES», 2021, 40, pp. 1169 - 1176 [articolo]Open Access
Gatti M.; Fusaroli M.; Raschi E.; Moretti U.; Poluzzi E.; De Ponti F., Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system, «EXPERT OPINION ON DRUG SAFETY», 2021, 20, pp. 1421 - 1431 [articolo]
Gatti M.; Fusaroli M.; Caraceni P.; Poluzzi E.; De Ponti F.; Raschi E., Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19, «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2021, 87, pp. 1533 - 1540 [articolo]
Gatti M.; Raschi E.; De Ponti F., Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis, «EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY», 2021, 77, pp. 233 - 239 [articolo]Open Access
